Cardiothoracic & vascular anesthesia
Preoperative SGLT2i therapy and acute kidney injury in patients undergoing emergency and urgent coronary artery bypass grafting - A causal inference framework
Main findingResult — go to the resultRelative risk 0.63 95 % CI 0.44–0.91Authors' conclusion
Preoperative SGLT2i use was associated with a significantly lower risk of CSA-AKI in patients undergoing urgent or emergent CABG.
Study context
- Population
- Adults undergoing urgent or emergent isolated coronary artery bypass grafting (CABG) with an indication for SGLT2i (type 2 DM, HF with reduced ejection fraction, or CKD), Medical University of Graz, 2020–2024
- Participants
- 484 adults
- Exposure
- Preoperative SGLT2i use vs no use
- SGLT2i usersn = 135
- Outcome
- Cardiac surgery-associated acute kidney injury (AKI) (CSA-AKI) by KDIGO criteria
Methodological detailssingle-centre, entropy balancing
- Single-centre
- Entropy balancing
Main finding
As reported in the abstract
Relative risk
0.63
95 % CI 0.44–0.91
P = 0.014
By group
SGLT2i users vs Non-users
RR 0.63 (95 % CI 0.44–0.91); P = 0.014
Observational data: associations, not effects.
Secondary outcomes
Cardiac surgery-associated AKI (CSA-AKI) in HF with reduced ejection fraction and high EuroSCORE II (subgroups)
- Association pronounced in patients with HF with reduced ejection fraction and those with high EuroSCORE II
Other secondary endpoints (RRT, ICU LOS, 30-day mortality)
- No differences observed
Safety
Postoperative diabetic ketoacidosis
- No cases occurred
Original publication
Preoperative SGLT2i therapy and acute kidney injury in patients undergoing emergency and urgent coronary artery bypass grafting - A causal inference framework. J Clin Anesth. Published 15 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →